Gov. Kathy Hochul has made significant investments in health care innovation and children’s health in New York, but the state’s Drug Utilization Review Board has paused Medicaid coverage for Sarepta Therapeutic’s FDA-approved gene therapy Elevidys, which could have a significant impact on patients.